|
|
News Breaks
|
November 23, 2009
|
| 09:26 EDT |  | OREX |
| theflyonthewall.com: | Orexigen trial data could increase obesity drug scrutiny, says Lazard Capital | | Lazard Capital believes data from Orexigen's SCOUT trial could lead to increased regulatory scrutiny of obesity drugs. However, the firm maintains a Buy rating on the stock with a $12 price target. :theflyonthewall.com |
|
|
News For OREX From The Last 14 Days Check below for free stories on OREX the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 6, 2012
|
| 08:12 EDT |  | OREX |
|
|
|
|
|
Subscribe for More Information